ArticleMagyar onkologia2026
[Very accelerated partial breast irradiation (VAPBI) with high-dose-rate interstitial brachytherapy following breast- conserving surgery of low-risk breast cancer patients].
Article in Magyar onkologia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo evaluate the efficacy and safety of high-dose-rate interstitial VAPBI in women undergoing conservative surgery for low-risk, early invasive breast cancer.
methodsBetween December 2018 and December 2024, 28 patients were enrolled in this prospective, non-randomized trial. Targeted radiotherapy of the tumor bed was delivered using thin plastic catheters placed at the surgical site, through which a high-dose-rate Ir-192 source was administered. Prescribed doses were 4×6.25 Gy (25 Gy total) or 3×7.45 Gy (22.35 Gy total), delivered over two consecutive working days.
resultsWith a median follow-up of 60 months (range: 9-84), local recurrence was observed in 2 patients (7.1%). One patient (3.6%) died of liver metastases, and another (3.6%) from a second primary tumor. The 5-year local control rate was 93.7% (95% CI: 88.1-99.4). Late toxicity was limited to grade 1 fibrosis in 6 patients (21.4%) and grade 1 pain in 2 patients (7.1%); no grade ≥2 toxicities occurred. Cosmetic results were excellent or good in all cases.
conclusionsReducing interstitial treatment duration from 5 to 2 days appears safe and more convenient for patients.
Indexed as
Identifiers
41819058PMC12990077What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.